title: Angiogenic functionalisation of titanium surfaces using nano-anchored VEGF - an in vitro study.
abstract: The aim of the present study was to test the hypothesis that sandblasted and acid etched titanium surfaces can be functionalised with vascular endothelial growth factor (VEGF) using oligonucleotides for anchorage and slow release. rhVEGF165 molecules were conjugated to strands of 30-mer non-coding DNA oligonucleotides (ODN) and hybridised to complementary ODN anchor strands which had been immobilised to the surface of sandblasted/acid etched (SAE) Ti specimens. Specimens with non-conjugated VEGF adsorbed to ODN anchor strands and to blank SAE surfaces served as controls. Specific binding of conjugated VEGF exhibited the highest percentage of immobilised VEGF (71.0 %), whereas non-conjugated VEGF only achieved 53.2 and 30.7 %, respectively. Cumulative release reached 54.0 % of the immobilised growth factor in the group of specifically bound VEGF after 4 weeks, whereas non-conjugated VEGF adsorbed to ODN strands released 78.9% and VEGF adsorbed to SAE Ti surfaces released 97.4 %. Proliferation of human umbilical vein endothelial cells (HUVECs) was significantly increased on the surfaces with specifically bound VEGF compared to the control surfaces and SAE Ti surfaces without VEGF. Moreover, the released conjugated VEGF exhibited biological activity by induction of von Willebrand Factor (vWF) in mesenchymal stem cells. It is concluded that the angiogenic functionalisation of SAE titanium surfaces can be achieved by conjugation of VEGF to ODN strands and hybridisation to complementary ODN strands that are anchored to the titanium surface. The angiogenic effect is exerted both through the immobilised and the released portion of the growth factor.
authors.affiliation: Dept. of Oral and Maxillofacial Surgery, George-Augusta-University, Robert-Koch-Str. 40, D-37075 Göttingen, Germany. schliephake.henning@med.uni-goettingen.de
authors.forename: H
authors.initials: H
authors.lastname: Schliephake
authors.forename: N
authors.initials: N
authors.lastname: Strecker
authors.forename: A
authors.initials: A
authors.lastname: Förster
authors.forename: B
authors.initials: B
authors.lastname: Schwenzer
authors.forename: J
authors.initials: J
authors.lastname: Reichert
authors.forename: D
authors.initials: D
authors.lastname: Scharnweber
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000378:metabolism; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D055767:Immobilized Proteins / Q000378:metabolism; D066298:In Vitro Techniques; D059630:Mesenchymal Stem Cells / Q000187:drug effects / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009841:Oligonucleotides / Q000737:chemistry / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D013499:Surface Properties; D014025:Titanium / Q000737:chemistry / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000378:metabolism*; D014841:von Willebrand Factor / Q000187:drug effects / Q000378:metabolism
chemical_list: D003692:Delayed-Action Preparations; D055767:Immobilized Proteins; D009841:Oligonucleotides; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D014841:von Willebrand Factor; D014025:Titanium